Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection

New England Journal of Medicine

Volumn 359, Issue 4, 2008, Pages 355-365

  Cooper, David A ^a   Steigbigel, Roy T ^b   Gatell, Jose M ^c   Rockstroh, Jurgen K ^d   Katlama, Christine ^e   Yeni, Patrick ^f   Lazzarin, Adriano ^g   Clotet, Bonaventura ^h   Kumar, Princy N ⁱ   Eron, Joseph E ^j   Schechter, Mauro ^k   Markowitz, Martin ^l   Loutfy, Mona R ^m   Lennox, Jeffrey L ⁿ   Zhao, Jing ^o   Chen, Joshua ^o   Ryan, Desmond M ^o   Rhodes, Rand R ^o   Killar, John A ^o   Gilde, Lucinda R ^o   Strohmaier, Kim M ^o   Meibohm, Anne R ^o   Miller, Michael D ^o   Hazuda, Daria J ^o   Nessly, Michael L ^o   Dinubile, Mark J ^o   Isaacs, Robin D ^o   Teppler, Hedy ^o   Nguyen, Bach Yen ^o   more..

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b STONY BROOK UNIVERSITY   (United States)

^c UNIVERSITY OF BARCELONA   (Spain)

^d UNIVERSITY OF BONN   (Germany)

^e PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^f BICHAT HOSPITAL   (France)

^g SAN RAFFAELE HOSPITAL   (Italy)

^h HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

ⁱ GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^j UNIVERSITY OF NORTH CAROLINA   (United States)

^k FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^l ROCKEFELLER UNIVERSITY   (United States)

^m UNIVERSITY OF TORONTO   (Canada)

ⁿ EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^o MERCK RESEARCH LABORATORIES   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

DARUNAVIR; ENFUVIRTIDE; INTEGRASE; PLACEBO; RALTEGRAVIR; TIPRANAVIR; VIRUS RNA;

ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; DRUG SENSITIVITY; DRUG USE; ETHNICITY; EVALUATION; FEMALE; GENE MUTATION; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; RACE DIFFERENCE; SEX DIFFERENCE; TREATMENT FAILURE; VIRUS RESISTANCE;

EID: 47949114939     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa0708978     Document Type: Article

References (17)

1. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Washington, DC: Department of Health and Human Services, January 29, 2008. (Accessed June 30, 2008, at http://aidsinfo.nih.gov/contentfiles/ AdultandAdolescentGL.pdf.)
2. Hammer SM, Saag MS, Schechter M, et al. Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA Panel. JAMA 2006;296:827-43.
3. Tozzi V, Zaccarelli M, Bonfigli S, et al. Drug-class-wide resistance to antiretrovirals in HIV-infected patients failing therapy: prevalence, risk factors and virological outcome. Antivir Ther 2006;11:553-60.
4. Richman DD, Morton S, Wrin T, et al. The prevalence of antiretroviral drug resistance in the United States. AIDS 2004;18:1393-401.
5. Lalezari JP, Henry K, O'Hearn M, et al. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med 2003;348:2175-85. [Erratum, N Engl J Med 2003;349:1100.]
6. Lazzarin A, Clotet B, Cooper D, et al. Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N Engl J Med 2003;348:2186-95.
7. Grinsztejn B, Nguyen BY, Katlama C, et al. Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial. Lancet 2007;369:1261-9.
8. Hazuda DJ, Felock P, Witmer M, et al. Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. Science 2000;287:646-50.
9. Espeseth AS, Felock P, Wolfe A, et al. HIV-1 integrase inhibitors that compete with the target DNA substrate define a unique strand transfer conformation for integrase. Proc Natl Acad Sci U S A 2000;97:11244-9.
10. Markowitz M, Nguyen B-Y, Gotuzzo E, et al. Rapid and durable antiretroviral effect of the HIV-1 integrase inhibitor raltegravir as part of combination therapy in treatment-naïve patients with HIV-1 infection: results of a 48-week controlled study. J Acquir Immune Defic Syndr 2007;46:125-33.
11. Steigbigel RT, Cooper DA, Kumar PN, et al. Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med 2008;359:339-54.
12. Food and Drug Administration. Antiviral Drugs Advisory Committee Meeting 9/5/2007: Merck, raltegravir tablets NDA 22-145 [applicant presentation]. (Accessed June 30, 2008, at http://www.fda.gov/ohrms/dockets/ac/07/slides/2007- 4314s1-04-merckisaacs.pdf.)
13. Clotet B, Bellos N, Molina J-M, et al. Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials. Lancet 2007;369:1169-78. [Erratum, Lancet 2008;371:116.]
14. Wang R, Lagakos SW, Ware JH, Hunter DJ, Drazen JM. Statistics in medicine - reporting of subgroup analyses in clinical trials. N Engl J Med 2007;357:2189-94.
15. Montaner J, Guimaraes D, Chung J, Gafoor Z, Salgo M, DeMasi R. Prognostic staging of extensively pretreated patients with advanced HIV-1 disease. HIV Clin Trials 2005;6:281-90.
16. Gallant JE, DeJesus E, Arribas JR, et al. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med 2006;354:251-60.
17. MacArthur RD, Novak RM. Maraviroc: the first of a new class of antiretroviral agents. Clin Infect Dis 2008;47:236-41.